prikaz prve stranice dokumenta Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
  Download
PDF 2.77 MB
Scientific paper - Original scientific paper
Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
Human Vaccines & Immunotherapeutics, 20 (2024), 1; 2301186. https://doi.org/10.1080/21645515.2023.2301186
Tzanakaki, Georgina; Cabrnochová, Hana; Delić, Snežana; Draganescu, Anca; Hilfanova, Anna; Onozó, Beáta; Pokorn, Marko; Skoczyńska, Anna; Tešović, Goran

Cite this document

Tzanakaki, G., Cabrnochová, H., Delić, S., Draganescu, A., Hilfanova, A., Onozó, B. ... Tešović, G. (2024). Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?. Human Vaccines & Immunotherapeutics, 20. (1). doi: 10.1080/21645515.2023.2301186

Tzanakaki, Georgina, et al. "Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?." Human Vaccines & Immunotherapeutics, vol. 20, no. 1, 2024. https://doi.org/10.1080/21645515.2023.2301186

Tzanakaki, Georgina, Hana Cabrnochová, Snežana Delić, Anca Draganescu, Anna Hilfanova, Beáta Onozó, Marko Pokorn, Anna Skoczyńska and Goran Tešović. "Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?." Human Vaccines & Immunotherapeutics 20, no. 1 (2024). https://doi.org/10.1080/21645515.2023.2301186

Tzanakaki, G., et al. (2024) 'Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?', Human Vaccines & Immunotherapeutics, 20(1). doi: 10.1080/21645515.2023.2301186

Tzanakaki G, Cabrnochová H, Delić S, Draganescu A, Hilfanova A, Onozó B, and sur.. Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?. Human Vaccines & Immunotherapeutics [Internet]. 2024 January 04 [cited 2025 January 11];20(1). doi: 10.1080/21645515.2023.2301186

G. Tzanakaki, et al., "Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?", Human Vaccines & Immunotherapeutics, vol. 20, no. 1, January 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:912176. [Accessed: 11 January 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
AuthorGeorgina Tzanakaki
AuthorHana Cabrnochová
AuthorSnežana Delić
AuthorAnca Draganescu
AuthorAnna Hilfanova
AuthorBeáta Onozó
AuthorMarko Pokorn
AuthorAnna Skoczyńska
AuthorGoran Tešović
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Infectious Diseases)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
Invasive meningococcal disease (IMD) is an acute life-threatening infection caused by the gram-negative bacterium, Neisseria meningitidis. Globally, there are approximately half a million cases of IMD each year, with incidence varying across geographical regions. Vaccination has proven to be successful against IMD, as part of controlling outbreaks, and when incorporated into national immunization programs. The South-Eastern Europe Meningococcal Advocacy Group (including representatives from Croatia, the Czech Republic, Greece, Hungary, Poland, Romania, Serbia, Slovenia and Ukraine) was formed in order to discuss the potential challenges of IMD faced in the region. The incidence of IMD across Europe has been relatively low over the past decade; of the countries that came together for the South-Eastern Meningococcal Advocacy Group, the notification rates were lower than the European average for some country. The age distribution of IMD cases was highest in infants and children, and most countries also had a further peak in adolescents and young adults. Across the nine included countries between 2010 and 2020, the largest contributors to IMD were serogroups B and C; however, each individual country had distinct patterns for serogroup distribution. Along with the variations in epidemiology of IMD between the included countries, vaccination policies also differ.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleHuman Vaccines & Immunotherapeutics
Numberingvol. 20, no. 1, 2301186
p-ISSN2164-5515
e-ISSN2164-554X
DOIhttps://doi.org/10.1080/21645515.2023.2301186
URN:NBNurn:nbn:hr:105:912176
Publication2024-01-04
Document URLhttps://www.tandfonline.com/doi/full/10.1080/21645515.2023.2301186
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2024-12-12 11:49:32